search
Back to results

Multimodal Neuroimaging in the Selection of Acute Ischemic Stroke (AIS) Patients to Endovascular Treatment (EVT) (IMAGECAT)

Primary Purpose

Ischemic Stroke, Arterial Occlusion, CTS

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)
MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)
Sponsored by
Germans Trias i Pujol Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Ischemic Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Without previous functional dependency evaluated by modified Rankin Score ≤2
  3. Regarding stroke severity (NIHSS≥ 6)
  4. Time from symptoms onset <24 hours

Exclusion Criteria:

  1. Clinical suspicion of vertebrobasilar occlusion (brainstem symptoms)
  2. MR contraindication or lack of concomitant availability of one or both neuroimaging techniques
  3. Severe kidney failure

Sites / Locations

  • Meritxell Gomis Cortina

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

MULTIMODAL MAGNETIC RESONANCE (MR)

MULTIMODAL COMPUTED TOMOGRAPHY (CT)

Arm Description

Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.

Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.

Outcomes

Primary Outcome Measures

To evaluate long-term clinical outcome in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Modified Rankin Scale (mRS) ordinal distribution in each group. The mRS measures the patient functional status. It range from 0 to 6, and the values are (0, 1, 2, 3, 4, 5 and 6). The 0 value indicate a patient completely functional independent and without neurological deficit and 6 value indicate death. The value 1 indicate a minor neurological deficit but the patient is fully independent, the value 2 indicate that the patient do not perform all his activities (like work) but is fully independent for the daily activities so can live alone without assistance, value 3 indicates a patient partially dependent taht can not live alone during more than a week, value 4 indicates a patient totally dependent in a wheelchair but able to be some hours without assistance, and value 5 indicates a patient totally dependent in bed.

Secondary Outcome Measures

To evaluate long-term good clinical outcome in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Modified Rankin Scale (mRS<3) in each group. The mRS measures the patient functional status. It range from 0 to 6, and the values are (0, 1, 2, 3, 4, 5 and 6). The 0 value indicate a patient completely functional independent and without neurological deficit and 6 value indicate death. The value 1 indicate a minor neurological deficit but the patient is fully independent, the value 2 indicate that the patient do not perform all his activities (like work) but is fully independent for the daily activities so can live alone without assistance, value 3 indicates a patient partially dependent taht can not live alone during more than a week, value 4 indicates a patient totally dependent in a wheelchair but able to be some hours without assistance, and value 5 indicates a patient totally dependent in bed.
To evaluate the rate of symptomatic intracerebral haemorrhage in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
To compare the rate of symptomatic intracranial haemorrhage
To evaluate mortality in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
To compare mortality at 7 days and 90 days
To evaluate the presence of vomiting during the acquisition technique in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
To compare vomiting during the acquisition technique time
To evaluate the presence of in-hospital pneumonia in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
To compare the rate of in-hospital pneumonia
Indication of EVT in each technique
Rate of ischemic stroke patients selected for endovascular treatment by each technique
Feasibility of multimodal neuroimaging to select patients for EVT
Door-picture time and door-groin puncture time in each technique and movement artifacts

Full Information

First Posted
May 28, 2018
Last Updated
June 28, 2022
Sponsor
Germans Trias i Pujol Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03745391
Brief Title
Multimodal Neuroimaging in the Selection of Acute Ischemic Stroke (AIS) Patients to Endovascular Treatment (EVT)
Acronym
IMAGECAT
Official Title
IMAGECAT Study: Multimodal Neuroimaging of Choice in the Selection of Patients With Acute Stroke and Favorable Clinical Response to Endovascular Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
November 13, 2018 (Actual)
Primary Completion Date
June 15, 2021 (Actual)
Study Completion Date
October 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Germans Trias i Pujol Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To study the feasibility and usefulness of multimodal MR compared to multimodal CT to select patients with acute ischemic stroke and favorable clinical outcome after mechanical thrombectomy. The specific objectives are to compare (1) the door-picture time and door-groin puncture time, (2) the rate of patients with acute stroke selected for endovascular treatment and (3) the safety and clinical response after thrombectomy between the two groups selected according to the imaging modality. Methodology: Single-center, randomized 1:1 and stratified by age and NIHSS study of consecutive patients with suspected acute ischemic stroke. Occlusion site, ischemic volume (core) and perfusion volume will be studied by an automated perfusion system (RAPID software) in both neuroimaging groups. Mechanical thrombectomy criteria will be basically based on the presence of a Large Vessel Occlusion (LVO) and a volume of core lower than 70cc in the Cerebral Blood Flow (CBF) or Diffusion Weighted Image (DWI) sequences. Modified Rankin scale at 90 days and the rate of intracranial hemorrhage and mortality will be considered as variables of response.
Detailed Description
In acute ischemic stroke, arterial occlusion lead to a brain ischemia that will progress to brain death of the ischemic area if the clot is not rapidly removed. Advanced neuroimaging can help us to distinguish between the irreversible injury brain parenchyma or core and the potential reversible ischemic tissue or penumbra. Multimodal neuroimaging techniques (MR and CT) have been developed in order to distinguish between core and penumbra areas and have been used to select patients in most of the last randomized clinical trials that have demonstrated the benefit of endovascular treatment. There is no agreement about which multimodal technique offers a better information to select patients for endovascular treatment. The main aim is to study the feasibility and usefulness of multimodal MR compared to multimodal CT to select patients with acute ischemic stroke and favorable clinical outcome after mechanical thrombectomy. The specific objectives are: Primary: to confirm no differences in long-term clinical outcome in patients with acute ischemic stroke and in those treated with endovascular therapy selected by multimodal CT or MR; and Secondary: (1) compare the feasibility of both techniques in this setting, (2) the door-picture time and door-groin puncture time of both techniques, (3) the safety of both techniques (sICH and in-hospital pneumonia) Methodology: Single-center, randomized (1:1) and stratified by age and NIHSS study of consecutive patients with acute ischemic stroke. Occlusion site, ischemic volume (core) and perfusion volume will be studied by an automated perfusion system (RAPID software) in both neuroimaging groups. Mechanical thrombectomy criteria will be basically based on the presence of an intracranial LVO occlusion and a volume of core lower than 70cc in the CBF or DWI sequences. Modified Rankin scale at 90 days and the rate of intracranial hemorrhage and mortality will be considered as variables of response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke, Arterial Occlusion, CTS, Magnetic Resonance Imaging

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be included consecutively and randomized (1:1) to Multimodal MR or Multimodal CT stratifying by age (<70, ≥70), stroke severity (NIHSS<18, ≥18) and time from onset to hospital (<8 hours, ≥8 hours)
Masking
Outcomes Assessor
Masking Description
A blinded neurologist investigator (M. Gomis) will perform the clinical assesment of included patients at 90 days in outpatient clinics
Allocation
Randomized
Enrollment
323 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MULTIMODAL MAGNETIC RESONANCE (MR)
Arm Type
Active Comparator
Arm Description
Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
Arm Title
MULTIMODAL COMPUTED TOMOGRAPHY (CT)
Arm Type
Active Comparator
Arm Description
Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
Intervention Type
Diagnostic Test
Intervention Name(s)
MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)
Intervention Description
After randomization, a MULTIMODAL MR will be performed to select treatment patient
Intervention Type
Diagnostic Test
Intervention Name(s)
MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)
Intervention Description
After randomization, a MULTIMODAL CT will be performed to select treatment patient
Primary Outcome Measure Information:
Title
To evaluate long-term clinical outcome in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
Modified Rankin Scale (mRS) ordinal distribution in each group. The mRS measures the patient functional status. It range from 0 to 6, and the values are (0, 1, 2, 3, 4, 5 and 6). The 0 value indicate a patient completely functional independent and without neurological deficit and 6 value indicate death. The value 1 indicate a minor neurological deficit but the patient is fully independent, the value 2 indicate that the patient do not perform all his activities (like work) but is fully independent for the daily activities so can live alone without assistance, value 3 indicates a patient partially dependent taht can not live alone during more than a week, value 4 indicates a patient totally dependent in a wheelchair but able to be some hours without assistance, and value 5 indicates a patient totally dependent in bed.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
To evaluate long-term good clinical outcome in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
Modified Rankin Scale (mRS<3) in each group. The mRS measures the patient functional status. It range from 0 to 6, and the values are (0, 1, 2, 3, 4, 5 and 6). The 0 value indicate a patient completely functional independent and without neurological deficit and 6 value indicate death. The value 1 indicate a minor neurological deficit but the patient is fully independent, the value 2 indicate that the patient do not perform all his activities (like work) but is fully independent for the daily activities so can live alone without assistance, value 3 indicates a patient partially dependent taht can not live alone during more than a week, value 4 indicates a patient totally dependent in a wheelchair but able to be some hours without assistance, and value 5 indicates a patient totally dependent in bed.
Time Frame
90 days
Title
To evaluate the rate of symptomatic intracerebral haemorrhage in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
To compare the rate of symptomatic intracranial haemorrhage
Time Frame
24-36 hours after stroke
Title
To evaluate mortality in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
To compare mortality at 7 days and 90 days
Time Frame
7-90 days after stroke
Title
To evaluate the presence of vomiting during the acquisition technique in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
To compare vomiting during the acquisition technique time
Time Frame
At 24 hours after stroke
Title
To evaluate the presence of in-hospital pneumonia in ischemic stroke patients, and those treated with EVT and selected by each multimodal technique
Description
To compare the rate of in-hospital pneumonia
Time Frame
During hospitalization after stroke (approximately 7 days)
Title
Indication of EVT in each technique
Description
Rate of ischemic stroke patients selected for endovascular treatment by each technique
Time Frame
Through study completion, approximately 1 year
Title
Feasibility of multimodal neuroimaging to select patients for EVT
Description
Door-picture time and door-groin puncture time in each technique and movement artifacts
Time Frame
Through study completion, approximately 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old Without previous functional dependency evaluated by modified Rankin Score ≤2 Regarding stroke severity (NIHSS≥ 6) Time from symptoms onset <24 hours Exclusion Criteria: Clinical suspicion of vertebrobasilar occlusion (brainstem symptoms) MR contraindication or lack of concomitant availability of one or both neuroimaging techniques Severe kidney failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Meritxell Gomis, MD PhD
Organizational Affiliation
Germans Trias i Pujol Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Meritxell Gomis Cortina
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08917
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Multimodal Neuroimaging in the Selection of Acute Ischemic Stroke (AIS) Patients to Endovascular Treatment (EVT)

We'll reach out to this number within 24 hrs